2023 ACCP Virtual Journal Club Webinar-February CPDD Edition | A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches-On-Demand
You must log in to register
- User - Free!
- Member - Free!
2023 ACCP Virtual Journal Club Webinar: A Review on Drug-Induced Nephrotoxicity: Pathophysiological Mechanisms, Drug Classes, Clinical Management, and Recent Advances in Mathematical Modeling and Simulation Approaches - On-Demand
Live webinar: February 16, 2023 from 2:00 - 3:00 PM ET
On-demand webinar recording: February 16, 2023 to February 16, 2026
Why is this article important to your practice?
Drug-induced nephrotoxicity (DIN) is a major clinical challenge for a variety of marketed drugs belonging to various therapeutic areas. Successful clinical prevention of DIN requires prior knowledge of drug’s mechanism of action coupled with pathogenic mechanisms of renal injury as well as patient- and drug-related risk factors. Recently, significant innovative advances in the identification of novel early biomarkers for DIN have been made. However, they are not beyond limitations. In such scenarios, mathematical modeling and simulation (M&S) may be used as a robust tool to understand and predict DIN in a clinical setting. This presentation highlights some of the recent advancements in mathematical M&S approaches for DIN. An example of the utility of multiscale and translational M&S for combinatorial effects of a DIN with a proposed preventive therapeutic will be showcased.
Physicians, Pharmacists, PhDs.
After completing this activity, the learner will be able to:
1) Review the various mechanisms of DIN and highlight the associated classes of nephrotoxic drugs;
2) Describe the current approach to prevention, diagnosis and management of drug-induced nephrotoxicity;
3) Summarize recent advances in the role of mathematical M&S in DIN.
Sihem Bihorel, PharmD, PhD
Principal Scientist-Scientific Director
Merck & Co Inc
Dr. Sihem Bihorel is currently a Principal Scientist (Scientific Director) at Merck & Co. Prior to joining Merck, she was an Assistant Professor at the College of Pharmacy at the University of Florida. Dr. Bihorel holds a Master's degrees in Immunology and in Pharmacometrics, a PharmD, and a PhD. Following her PhD research conducted in the Department of Pharmaceutical Sciences at SUNY at Buffalo, she pursued a Postdoctoral Associate position, followed by a Research Assistant Professor position in the same department. Her expertise is in the end-to-end application of model-informed drug development with a variety of quantitative approaches and in various therapeutic areas. Sihem has authored numerous scientific publications in international peer-reviewed journals, book chapters, and presented her work as posters, talks, and webinars at various international conferences. She is also a mentor to many students, postdocs, scholars, and scientists in academia, the pharmaceutical industry, and the International Society of Pharmacometrics.